Merck & Co. (MRK) Melanoma Drug Shrinks Tumors in 38 Percent of Patients: Study
6/3/2013 7:30:05 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
A Merck & Co drug designed to unmask tumor cells and mobilize the immune system into fighting cancer helped shrink tumors in 38 percent of patients with advanced melanoma in an early-stage study, U.S. researchers said on Sunday.
Based on the findings about the drug lambrolizumab, published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology meeting in Chicago, Merck says it will move directly into a late-stage clinical trial, which will start in the third quarter.
Help employers find you! Check out all the jobs and post your resume.
comments powered by